1. Delirium in the 'young' covid-19 patient (<65 years): Preliminary clinical indications
- Author
-
DI GIACOMO, E, Colmegna, F, Santorelli, M, Pessina, R, D'Amico, E, Marcatili, M, Dakanalis, A, Pavone, F, Fagiolini, A, Clerici, M, DI GIACOMO E., COLMEGNA F., SANTORELLI M., PESSINA R., D'AMICO E., MARCATILI M., DAKANALIS A., PAVONE F., FAGIOLINI A., CLERICI Massimo., DI GIACOMO, E, Colmegna, F, Santorelli, M, Pessina, R, D'Amico, E, Marcatili, M, Dakanalis, A, Pavone, F, Fagiolini, A, Clerici, M, DI GIACOMO E., COLMEGNA F., SANTORELLI M., PESSINA R., D'AMICO E., MARCATILI M., DAKANALIS A., PAVONE F., FAGIOLINI A., and CLERICI Massimo.
- Abstract
Delirium is a phenomenon classified within neuro-cognitive disorders in the DSM-5. It has several etiologies and it is often lethal. This contribute aims at analyzing clinical characteristics and diagnostic possibilities of delirium in patients affected by covid-19. Furthermore, some preliminary recommendations on the use of psychopharmacological treatment of delirium and their interactions with main drugs used to treat covid-19 are given, with a special attention to comorbidities like in immunocompromised patients, in those affected by diabetes and cancer, in pregnant women or in addicted clients.
- Published
- 2021